Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Share-based Compensation (2016 - 2025)

Standard Biotools (LAB) has disclosed Share-based Compensation for 16 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 41.45% to $6.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $41.1 million, a 171.9% increase, with the full-year FY2024 number at $31.7 million, up 141.8% from a year prior.
  • Share-based Compensation was $6.6 million for Q3 2025 at Standard Biotools, up from $5.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $20.1 million in Q4 2024 to a low of -$4.6 million in Q2 2024.
  • A 5-year average of $5.1 million and a median of $4.3 million in 2021 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 478.56% in 2024; the steepest drop was 248.78% in 2024.
  • Standard Biotools' Share-based Compensation stood at $4.4 million in 2021, then crashed by 61.47% to $1.7 million in 2022, then surged by 106.72% to $3.5 million in 2023, then skyrocketed by 478.56% to $20.1 million in 2024, then plummeted by 67.29% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Share-based Compensation are $6.6 million (Q3 2025), $5.4 million (Q2 2025), and $9.0 million (Q1 2025).